Relugolix for Endometriosis

"Relugolix is an effective treatment for advanced androgen dependent prostate cancer, no menstrual period in previous 6 months, and hypoestrogenism."

"This trial is only open to patients aged 18-51. If you are under 18, there are 13 other clinical trials you may be eligible for. If you are over 65, there are 38 other clinical trials you may be eligible for."

"As of now, there are 62 ongoing studies on the efficacy of Relugolix. Out of these, 11 are in Phase 3. Moreover, Relugolix trials are not limited to Greensboro, North carolina- there are 1059 clinical trial sites for Relugolix across the globe."

"Like other Phase 3 drugs, Relugolix has undergone multiple rounds of testing to ensure its efficacy and safety. Our team at Power gave it a score of 3."

"Out of the total 58 clinical trial sites, this study is recruiting patients from Shawnee Mission, Corpus Christi, Hialeah, and 55 other locations. If you enroll in this trial, it is important to choose a location near you to reduce travel."

"This study is open to 803 people with endometrioma between the ages of 18 and 51. To be eligible, patients must meet the following criteria: Completed 24 weeks of study drug treatment and study participation in either parent study, MVT-601-3101 or MVT-601-3102., Is not expected to undergo gynecological surgery or other surgical procedures for treatment of endometriosis (including ablation, shaving, or excision) during the study, including during the Follow-Up Period, and the participant does not desire such treatment during this time frame., Has agreed to continue to use only"

"Unfortunately, this particular trial is not seeking patients at the moment. Although, it is worth noting that there are other154 trials with open recruitment at this time. This specific trial was posted on May 22nd, 2018 and was last updated on May 31st, 2022."

"Unfortunately, this study has already reached its recruitment goal and is no longer searching for new participants. If you are interested in other studies, there are 92 trials actively recruiting participants with endometrioma and 62 studies for Relugolix admitting patients."

"The goal of this trial is to Proportion Of Women Who Respond Or Maintain Response Based On Assessment Of Dysmenorrhea At Week 52 And Week 104. Secondary outcomes include Change From Parent Study Baseline In Overall NRS Scores At Week 52 And Week 104 which is defined as Assessed using a NRS score (11-point scale) for overall pain recorded daily in an e-Diary., Change From The Parent Study Baseline In Function Due To Endometriosis-associated Pain At Week 52 And Week 104 which is defined as Assessed using the Pain Domain of the Endometriosis Health Profile (EHP)-30"